Concordance rates for TP53 mutations between breast cancer tissue and plasma are extremely different across studies, which might be dependent on disease subtype or stage [49] but also might be affected by time sampling bias, technology used for NGS analysis or the VAF for each TP53 mutation presented in each patient. The gene discussed is TP53; the disease is breast cancer.